Practical Guidance on Mental Health and Physician Burnout

Latest News

The Clinical Trial Disparity: Why So Few Black Patients Enroll

In trials for 24 of the 31 cancer drugs approved since 2015, fewer than 5% of participants were Black. As a result of this disparity, Black patients aren't getting access to experimental, and possibly lifesaving new therapies.

Learn More

The Evolution of Telemedicine – Considering Patients Who Don’t have WiFi

By Kayle Waterhouse As physicians adapt to a world in which connecting with patients over video has become a part of their day to day lives, there is significant debate about the effectiveness of telemedicine. In SurvivorNet’s virtual conference about reducing racial disparities in multiple myeloma, leading oncologists shared different views on telemedicine.  “Unfortunately, not […]

Learn More

The Evolution to BTK Inhibitors in CLL Treatment

Chronic lymphocytic leukemia (CLL) treatment used to be one-size-fits-all. Today, the approach has shifted to more targeted therapies, thanks to the introduction of the Bruton's tyrosine kinase (BTK) inhibitors. Dr. James Gerson, hematologist-oncologist at Penn Medicine, tells SurvivorNet Connect that he prefers acalabrutinib (brand name: Calquence) because it has fewer side effects than ibrutinib in a similar patient population.

Learn More

The Latest Efforts to Preserve the Bladder

In solid tumors affecting organs, efforts have been made to preserve the organ while still eradicating the cancer. The same is true for bladder cancer. Radical cystectomy with pelvic lymph node dissection is a highly morbid procedure, which is often performed in patients who are already elderly and frail.

Learn More

The Message from Leading Voices in Cancer Care — Don’t Lose Yourself in Caring for Your Patients

Physician burnout is real. The mental and physical exhaustion that characterizes this condition affects up to half of doctors, and it can have both professional and personal implications. Even in times of great duress, like the COVID-19 pandemic, our instinct is to put patients first, and we may fail to recognize our own needs as a result.

Learn More

The PACIFIC Trial Marks Major Breakthrough in Stage III Lung Cancer Treatment

Nearly one-third of patients with non-small cell lung cancer (NSCLC) present at stage III, most with unresectable tumors. Treatments up to now have had limited success with these patients, who have faced a median survival time of approximately two years. Thanks to durvalumab (brand name: Imfinzi), the outlook is finally looking up.

Learn More

The Promise of CAR T-Cell Therapy for Multiple Myeloma

Chimeric antigen receptor (CAR) T-cell therapy is showing great promise in multiple myeloma, with response rates in studies of 85% or more, and about half of patients going into complete remission for a year or longer.

Learn More

The Pros and Cons of a Patient’s HRD Score

Homologous recombination deficiency (HRD) score is an emerging marker to predict an ovarian cancer patient’s response to PARP inhibitors. However, its use is complicated by a lack of standardization between the molecular diagnostic companies.

Learn More